Authors
Latest:
Acne Update: 2022’s Top 5 TrendsFresh spins on established treatments and newly FDA-approved drugs and devices provide a framework for changing therapies and modalities for acne regimens.
Latest:
Expert Insights Into the Relationship Between the Hippo Pathway and Extensive Fibrosis in HSResearchers from the University of Michigan and Almirall found that the profibrotic fibroblast response in HS can be modulated through inhibition of the Hippo pathway.
Latest:
Mike Siegel, PhD: What's Coming Up in 2024 for PeDRAIn an interview with Dermatology Times, the executive director of Pediatric Dermatology Research Alliance (PeDRA) discusses the group's growth since 2012 and what it can offer practicing dermatologists, researchers, students, and patients.
Latest:
Expert Perspectives on BOLT clinical trial dataJohn Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.
Latest:
COVID-19 study shows impact on patients with PsO, other autoimmune problemsArdon Health patients with autoimmune conditions have expressed common questions and concerns about COVID-19.
Latest:
The Weekly Roundup: June 9-13In case you missed it, this week we had news about abrocitinib's flexible dosing for atopic dermatitis, plant-derived exosomes in regenerative skin care, psychosocial support in hidradenitis suppurativa care, and more.
Latest:
Optimizing MOAs of JAK Inhibitors in a 36-Year-Old Male With a History of Atopic DermatitisJayme Heim, MSN, FNP-BC, explores strategies for optimizing the mechanisms of action of topical JAK inhibitors in treating a 36-year-old male patient with a history of atopic dermatitis, highlighting the potential benefits and considerations of this therapeutic approach.
Latest:
Provider and Patient Considerations for Prurigo Nodularis TreatmentMelodie Young, MSN, A/GNP-C, discusses how clinical and practical considerations, such as disease severity, patient preferences, and comorbidities, should guide the selection of treatment for prurigo nodularis, and emphasizes the importance of educating patients about the role of systemic therapies, addressing their concerns, and improving awareness of available treatment options.
Latest:
Photodynamic Pearls and Best PracticesMonica Boen, MD, discusses how implementing proven photodynamic therapy techniques and adhering to best practices can significantly improve treatment outcomes and patient satisfaction.
Latest:
Dealing With Student Loan Debt: How to Budget for Repayment and Other Financial GoalsIn this month’s Finance & Practice Management column, we illustrate the importance of developing and maintaining a budget for physicians at all stages of their careers.
Latest:
Examining the Halfway Mark of 2025 in DermatologyDiscover the latest advancements in dermatology in our June issue, including FDA approvals, innovative treatments, and expert insights shaping patient care today.
Latest:
Partner with Hair Stylists and Give Them the Knowledge to Spot Scalp ConcernsThe HEROES program wants to make it easier for stylists to recognize scalp conditions and advise their clients to seek medical help.
Latest:
Meena Julapalli, MD: Finding and Prioritizing Joy in the Pediatric Dermatology SpecialtyJulapalli discusses her SPD 2024 lecture, "Rediscovering Joy in our Lives and the Workplace," excitement for the future of pediatric dermatology, and more.
Latest:
Topical Skin Care Probiotics Made With New Technology Yield Numerous BenefitsThe benefits include more accurate bacteria cell counts, more efficacious strains, and improved shelf life compared to non-heat-treated probiotics.
Latest:
Evaluating Lifileucel and Pembrolizumab in Advanced MelanomaPeter Prieto, MD, MPH, shares details of the IOV-COM-202 trial.
Latest:
Reviewing 3 Key Lebrikizumab Abstracts From AAD 2025Anabela Cardoso, MD, discussed lebrikizumab’s efficacy in improving itch, skin pain, sleep disturbance, and long-term management in atopic dermatitis.
Latest:
Clinical Insights Into Challenging Atopic Dermatitis Cases: Part 3Robert Posnick, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis involving hyperpigmentation and alopecia areata.
Latest:
Women with Psoriasis More Likely to Discontinue Biologics Than Men, Study FindsA recent study reveals that women with psoriasis are more likely to discontinue biologic treatments, including IL-17 and IL-23 inhibitors, due to adverse events and treatment dissatisfaction.
Latest:
SDPA Literature Review Session Shares Clinical PearlsThis special literature review yields a deeper understanding of issues like treating acne, nutraceuticals, and more.
Latest:
Five Financial Ratios to Watch to Track Your Practice’s Financial HealthThese ratios will help you determine the level of financial stability of your practice and help you make better decisions for your future.
Latest:
Nearly half of FDA-authorized AI tools may be ineffectiveResearchers stated the lack of reported clinical validation data raises concerns about their effectiveness and safety.
Latest:
Nonablative Lasers Offer a Gentle Approach to Healthy SkinIn honor of National Healthy Skin Month, it is the perfect time to encourage patients to integrate gentle laser treatments into their yearly routine to maintain healthy, radiant skin.
Latest:
Cutaneous Lupus Considerations with Joseph Merola, MD, MMScDiscover the evolving landscape of lupus treatment, from the importance of monitoring vitamin D levels to advancements in emerging therapies targeting type 1 interferon and plasmacytoid dendritic cells.
Latest:
Advances in HS treatment with Chris Sayed, MDUnlike previous therapies, bimekizumab has shown continued efficacy at 48 and 96 weeks, offering long-term benefits to HS patients.
Latest:
Treatment Switches and the Future of Hidradenitis Suppurativa ManagementPanelists discuss how identifying optimal timing for treatment switches and emerging therapeutic innovations are reshaping the management landscape for hidradenitis suppurativa, with the potential to improve long-term patient outcomes.
